inotersen ATTR historical
Selected indexed studies
- Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy. (JAMA, 2023) [PMID:37768671]
- Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform. (J Neurol, 2024) [PMID:39138650]
- Inotersen (transthyretin-specific antisense oligonucleotide) for treatment of transthyretin amyloidosis. (Neurodegener Dis Manag, 2019) [PMID:30561247]
_Worker-drafted node — pending editorial review._
Connections
inotersen ATTR historical is a side effect of
Sources
- Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy. (2023) pubmed
- Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform. (2024) pubmed
- Inotersen (transthyretin-specific antisense oligonucleotide) for treatment of transthyretin amyloidosis. (2019) pubmed
- Pharmacotherapy review: Emerging treatment modalities in transthyretin cardiac amyloidosis. (2022) pubmed
- Cardiac Amyloidosis: A Review of Current Imaging Techniques. (2021) pubmed
- Advancing Transthyretin Amyloidosis Drug Development in an Evolving Treatment Landscape: Amyloidosis Forum Meeting Proceedings. (2024) pubmed
- Reduction in (99m)Tc-DPD myocardial uptake with therapy of ATTR cardiomyopathy. (2024) pubmed
- Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy: An Exploratory Analysis of Treatment Effect in Male and Female Patients. (2026) pubmed